Description
The first oral antiviral drug, Favipiravir 200 mg tablets, was introduced by Glenmark Pharmaceutical under the trade name FaviFlu to treat mild to severe COVID-19 cases. In global clinical trials, this medication has demonstrated 80–88% efficacy. It is presently being used in Japan and the United Arab Emirates to treat COVID-19.
The Indian drug regulator authorized the oral consumption of Faviflu on June 19, 2020.
Dosage and Side Effects
Oral administration of favipiravir is recommended at around the same time every day, with or without food. Tablets containing favipiravir should be taken whole with water. It is not recommended to chew, break, or open the tablet. Adult COVID-19 patients typically receive 1800 mg of favipiravir orally twice a day on day 1, then 800 mg of the same medication twice a day for the next 14 days.
The Fabiflu frequently causes gastrointestinal distress, asthma attacks, hay fever, allergic dermatitis, edema throughout the body, and miscarriages.
Because favipiravir may harm the fetus, its usage during pregnancy is restricted.
FAQ's
What applications does Favipiravir have?
An antiviral drug called favipiravir combats both type A and type B influenza viruses. The mild to severe Covid-19 infection is treated with it. It prevents influenza A and B from replicating.
What components make up Favipiravir?
Favipiravir is the active ingredient; povidone, colloidal silicon dioxide, crospovidone, low-substituted hydroxypropyl cellulose, sodium stearyl fumarate, hypromellose, titanium dioxide, talc, and yellow ferric oxide are the inactive ingredients.
How should Favipiravir medication be stored?
The Favipiravir tablets should be kept at room temperature.